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Deciphering the complex role of thrombospondin-1
in glioblastoma development
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Jean-Jacques Feige11, Hrvoje Miletic3,12, Marco Rossi 13, Lorenzo Bello13, Francesco Falciani5,
Rolf Bjerkvig3,4,14 & Andréas Bikfalvi1,2
We undertook a systematic study focused on the matricellular protein Thrombospondin-1
(THBS1) to uncover molecular mechanisms underlying the role of THBS1 in glioblastoma
(GBM) development. THBS1 was found to be increased with glioma grades. Mechanistically,
we show that the TGFβ canonical pathway transcriptionally regulates THBS1, through SMAD3
binding to the THBS1 gene promoter. THBS1 silencing inhibits tumour cell invasion and
growth, alone and in combination with anti-angiogenic therapy. Speciﬁc inhibition of the
THBS1/CD47 interaction using an antagonist peptide decreases cell invasion. This is con-
ﬁrmed by CD47 knock-down experiments. RNA sequencing of patient-derived xenograft
tissue from laser capture micro-dissected peripheral and central tumour areas demonstrates
that THBS1 is one of the gene with the highest connectivity at the tumour borders. All in all,
these data show that TGFβ1 induces THBS1 expression via Smad3 which contributes to the
invasive behaviour during GBM expansion. Furthermore, tumour cell-bound CD47 is impli-
cated in this process.
https://doi.org/10.1038/s41467-019-08480-y OPEN
1 INSERM U1029, Institut Nationale de la Santé et de la Recherche Médicale, 33615 Pessac, France. 2 University Bordeaux, 33615 Pessac, France. 3 KG Jebsen
Brain Tumor Research Center, University of Bergen, 5020 Bergen, Norway. 4Norlux Beuro-Oncology, Department of Biomedicine, University of Bergen, 5020
Bergen, Norway. 5 Computational Biology Facility, University of Liverpool, Liverpool L69 7ZB, UK. 6 UMR1218 ACTION, Bioinformatic Center CBiB, University
of Bordeaux, 33076 Bordeaux, France. 7 Animal Facility, University Bordeaux, 33615 Pessac, France. 8 INSERM U1215, Neurocenter Magendie,
Pathophysiology of Addiction Group, 33076 Bordeaux, France. 9 CNRS UMR 7369, MEDyC, 51687 Reims, France. 10 SATT Nord, 59800 Lille, France.
11 INSERM U1036, Grenoble 38000, France. 12 Department of Pathology, Haukeland University Hospital, 5020 Bergen, Norway. 13 Neurosurgical Oncology
Unit, Department of Oncology and Hemato-Oncology, Humanitas Research Hospital, Universita Degli Studi di Milano, 20089 Rozzano, Milan, Italy.
14 Oncology Department, Luxembourg Institute of Health, 84, Val Fleuri 1526, Luxembourg. These authors contributed equally: Rolf Bjerkvig, Andréas Bikfalvi.
Correspondence and requests for materials should be addressed to T.D. (email: thomas.daubon@u-bordeaux.fr)
or to A.B. (email: andreas.bikfalvi@u-bordeaux.fr)
NATURE COMMUNICATIONS |         (2019) 10:1146 | https://doi.org/10.1038/s41467-019-08480-y | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
G liomas are classiﬁed by the WHO in four grades whereglioblastoma (GBM) represents the most aggressiveform1. GBMs are diagnosed based on their neuropatho-
logical features including mitotic activity, diffuse invasion, and
extensive angiogenesis and necrosis, the latter associated with
blood–brain barrier disruption2. Cell invasion represents a key
challenge for effective drug delivery and may be induced by anti-
VEGF therapy3.
The extracellular matrix (ECM), composed of ﬁbrous proteins
and glycoproteins, was ﬁrst acknowledged for its scaffolding role,
but is now recognised to have a role in numerous physiological
and pathological processes4. This includes tumour development
and metastasis5, where there is a striking difference between the
ECM of normal tissue as compared with tumours6. The throm-
bospondins, a family of ﬁve members (THBS1-5), are important
components of the ECM7. THBS1 was ﬁrst discovered in platelets
but has now been shown to have an important role in cancer
development8,9. Besides having a direct role in regulating tumour
cell behaviour, THBS1 also exhibits functions in the tumour
vasculature10. Numerous studies on several cancer types includ-
ing GBM11 indicate that THBS1 can modulate immune responses
as well as GBM vascularisation12. However, the precise con-
tributions of THBS1 in GBM development as well as its regula-
tion have not yet been fully determined.
Crosstalk between tumour and endothelial cells are driven by
several factors including VEGF and TGFβ1, the latter being
known to have a central role in GBM development13. We have
previously shown that THBS1 is expressed in tumour blood
vessels and in speciﬁc patient-derived xenograft (PDX) models14.
It has been proposed that THBS1 activates TGFβ1 via its type 1
domain by mobilising its active form from the Latent Activating
Protein (LAP)15. However, this may apply only to some but not
all tumour types and it is still a matter of debate16. It has also not
been established how TGFβ1 itself is able to regulate THBS1
expression17. THBS1 interacts with many effector proteins,
including α6β1 or α4β1 integrins, as well as with cell-surface
receptors such as CD36 and CD477. THBS1/CD47 interactions
have been reported to be important in vascularisation and
tumour progression18, but have not been associated with GBM
growth.
In this study, global expression analysis revealed THBS1 to be
upregulated in high-grade gliomas and to be associated with a
poor prognosis. Furthermore, we found that TGFβ1 activation
was not regulated by THBS1 in GBM, but on the contrary, TGFβ1
induced THBS1 expression through direct transcriptional acti-
vation via SMAD3. Our data show that THBS1 is not only
involved in the regulation of angiogenesis in GBM, but also
impacts the invasive behaviour of glioma cells and that THBS1/
CD47 interactions contributes to this process. Finally, we per-
formed gene expression analysis by RNA-sequencing after
microdissection of central and peripheral tumour areas in a
human PDX model3,19. We show striking differences between
both areas in the tumour and stromal cell compartments. In this
analysis, THBS1 was the gene with the highest connectivity in the
peripheral tumour areas.
Results
THBS1 is differently expressed between the glioma grades.
THBS1 has a role in tumour invasion in vivo in prostate cancer9
and medulloblastoma20, but its putative role in GBM invasion has
not been explored so far. We have previously shown that THBS1
is expressed in tumour blood vessels and in speciﬁc PDX mod-
els14. According to The Cancer Genome Atlas (TCGA), THBS1
expression is found to be increased in GBMs when compared to
grade II and III tumours (Supplementary Fig. 1A), and linked to
patient survival (Supplementary Fig. 1B). TGFβ1 expression was
only slightly upregulated in high-grade gliomas (Supplementary
Fig. 1A) and linked to survival (Supplementary Fig. 1B).
THBS1 was assessed for expression in patient samples of
glioma grade II, III and IV by immunohistochemistry (IHC)
(Fig. 1a). THBS1 was expressed at higher levels in GBM when
compared to glioma grades II, III, or normal brains (Fig. 1b).
When patient GBM tumour samples from multiple areas were
analysed by IHC, a speciﬁc pattern of THBS1 staining was seen
in the central tumour area and at the location of invasive cells
(Supplementary Fig. 2A, B). THBS1 was detected in both, tumour
vessels and tumour cells, the latter being enhanced in the
peripheral invasive areas (margin) (Supplementary Fig. 2A, B).
Signiﬁcant colocalisation between THBS1 and the hypoxia
marker CAIX (Carbonic Anhydrase IX) was detected in the
patient GBM core, but only single positive cells (CAIX or THBS1)
were detected in the invasive area (Supplementary Fig. 2C).
The P3 human xenograft model has previously been char-
acterised in several studies3,21,22. P3 give rise to tumours that
show a close resemblance to human GBMs, exhibiting a necrotic
core surrounded by pseudo-palisading cells as well as angiogenic
and invasive areas14. IHC of P3 xenografts demonstrated higher
THBS1 deposits within invasive areas (Fig. 1c, right panel)
(Nestin staining of the invasive area of the corpus callosum is
shown in Fig. 1c, left panel).
TGFβ1 controls THBS1 expression via SMAD3 binding. We
have previously shown that inactivation of the stress response
protein IRE1 leads to a change from an angiogenic to an invasive
phenotype in U87 tumours23. In this case, THBS1 was found to
be the most upregulated gene at both the mRNA and protein
level23. Western blot analyses conﬁrmed THBS1 upregulation in
U87 IRE1dn cells, in which Xbp1 is not spliced, as compared with
U87 control cells (Supplementary Fig. 3A). Furthermore, TGFβ1
activity was found increased in IRE1dn vs control cells as
demonstrated by measurements of active TGFβ1 (Supplementary
Fig. 3B) and nuclear localisation of P-SMAD2 (Supplementary
Fig. 3C). This suggested a link between TGFβ activity and THBS1
expression in our glioma model. To investigate the putative
involvement of THBS1 in direct TGFβ activation, U87wt cells
transfected with a SMAD luciferase reporter were incubated with
recombinant THBS1 to monitor TGFβ activation (Supplementary
Fig. 3D). Alternatively, U87wt cells stimulated with recombinant
THBS1 were probed by western blot for TGFβ effectors (P-
SMAD2 and FIBRONECTIN), and for PHOSPHO-AKT as a
control of THBS1 receptor activation (Supplementary Fig. 3E, left
panel). Under these conditions, THBS1 did not modulate the
TGFβ pathway in the presence or absence of LSKL peptide, a
putative inhibitor of THBS1/latent-activating protein interac-
tion24 (Supplementary Fig. 3D–E). However, P-AKT increase was
seen after short-term THBS1 stimulation (Supplementary Fig. 3E,
right panel). Furthermore, we demonstrated that knockdown of
THBS1 in U87 IRE1dn cells, which endogenously express high
levels of THBS123 (Supplementary Fig. 3A), had no effect on both
the concentration of active TGFβ in the medium (200–300 pg/106
cells, Supplementary Fig. 3F) or TGFβ activity measured by
nuclear P-SMAD2/3 accumulation (Supplementary Fig. 3G).
These results indicate that THBS1 has no direct role in TGFβ
activation in the glioma model.
The patient-derived cell line P3 and U87 cells similarly
responded to short-term TGFβ1 induction by increasing SMAD2
and SMAD3 phosphorylation (Supplementary Fig. 4A). After
longer TGFβ1 stimulation, we found an increase in THBS1
expression in both P3 and U87 cells (respectively, 2.6 ± 0.007-
and 6.94 ± 0.17-fold increase of THBS1 mRNA, 1.95 ± 0.16- and
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1.67 ± 0.07-fold increase of THBS1 protein expression) (Fig. 2a).
To corroborate our observations, we stimulated two other
patient-derived cell lines (BL9 and BL13) with recombinant
TGFβ1, and observed a time-dependent increase in THBS1
expression (Supplementary Fig. 4B). THBS1 expression was only
increased after TGFβ1 stimulation, not after TGFβ2, EGF, PDGF-
BB, or IL-1β stimulation (Supplementary Fig. 4C). Immunostain-
ing revealed that THBS1 appeared as small aligned dots along cell
protrusions that were further increased under TGFβ1 stimulation
(Supplementary Fig. 4D). THBS1 expression and secretion were
measured by ELISA in both cell extracts and in the extracellular
environment (free-THBS1) (Fig. 2b). Induction by TGFβ1 was
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Fig. 1 THBS1 is a marker of high-grade glioma. a Immunohistochemistry (IHC) of THBS1 in patient samples from grade II astrocytomas and
oligodendrogliomas (upper panels), grade III anaplastic astrocytomas and anaplastic oligodendrogliomas (middle panels) and grade IV glioblastomas
(lower panels). Magniﬁcation of tumour areas is shown in each panel on the right hand side. Scale: 50 µm. Quantiﬁcation of THBS1 staining by IHC
proﬁler from Fiji software. A, astrocytomas (n= 5); O, oligodendrogliomas (n= 5); AA, anaplastic astrocytomas (n= 5); AO, anaplastic
oligodendrogliomas (n= 5); and GBM, glioblastomas (n= 5). The graph represents the results as means ± s.d. **P < 0.01; ***P < 0.001; ****P < 0.0001;
ns not signiﬁcant (ANOVA). b Quantiﬁcation of THBS1 staining by using tissue microarrays. 121 patients were analysed using TMA (Biomax), and
IHC with anti-THBS1 antibodies. 57 were of grade II, 27 of grade III and 37 of GBM–grade IV. The graph represents the results as means ± s.d. **P < 0.01;
****P < 0.0001 (ANOVA). c Left panels: immunoﬂuorescence stainings of CD31 (red) and Nestin (green) of a P3 tumour section. Images below represent
core and invasive areas. Scales: 500 µm (upper panel) and 20 µm (lower panels). Right panels: IHC for THBS1 in samples representing core and invasive
areas in P3 tumours, counterstained with haematoxylin. THBS1 is expressed in invasive areas of P3 tumours. Scale: 50 µm
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completely blocked by the speciﬁc TGFβ receptor inhibitor,
LY2157299, in cell lysates, but also in supernatants (Fig. 2b). To
analyse canonical downstream signalling of TGFβ1, immunos-
tainings for P-SMAD2, P-SMAD3 and SMAD4 were performed.
All SMAD proteins were found to be located in the nuclei of U87
cells after TGFβ1 stimulation (Fig. 2c). Only binding sites for
Smad3 were found in the human THBS1 promoter. These are
located at −1125/−1115 for site 1 and at −110/−100 for site 2
(Fig. 2d). Importantly, SMAD3 silencing by siRNAs decreased
TGFβ1-induced THBS1 expression with a stronger effect for
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SMAD3-2 siRNA (Supplementary Fig. 5A, B). To acquire a
deeper understanding of THBS1 transcriptional regulation, we
mutated the putative SMAD3-binding sites on the THBS1
promoter and transduced P3 and U87 cells with these constructs.
Luciferase experiments showed that THBS1 promoter activity is
inhibited when the second SMAD3-binding site was mutated,
while increased when the ﬁrst binding site was mutated (Fig. 2e).
These results indicate a direct role for canonical TGFβ1 signalling
in controlling THBS1 transcriptional activity via SMAD3.
THBS1 impacts on tumour expansion and invasion. First, a
THBS1 shRNA strategy was employed to inhibit THBS1
expression in U87wt cells. THBS1 expression was strongly
reduced with both shRNAs (Supplementary Fig. 6A). Further-
more, invasion was signiﬁcantly decreased in THBS1-knockdown
U87 cells compared to control cells (Supplementary Fig. 6B).
In P3 spheroids, THBS1-knockdown (Supplementary Fig. 7A)
led to a signiﬁcant reduction in cell invasion when tested in a
collagen type I invasion assay (Fig. 3a). Knockdown
THBS1 spheroids were then orthotopically implanted in mice,
and tumours were then analysed by IHC (Supplementary
Fig. 7B). Differences in vessel type were found in the THBS1-
depleted tumours when compared to control, with a decrease
in small vessel number (<10 µm length) and an increase in
medium size vessels (between 10 and 20 µm length) (Fig. 3b).
Contra-lateral invasion was signiﬁcantly decreased by more than
49% for P3 THBS1-1 shRNA tumours and 76% for P3 THBS1-2
shRNA tumours in comparison with shRNA control tumours
(Fig. 3b). Survival was signiﬁcantly increased for mice implanted
with P3 tumours transduced with either one of the
THBS1 shRNA constructs (Fig. 3c). To reinforce these results,
we performed a gain-of-function experiment by expressing
THBS1 in P3 cells using a lentiviral construct. Overexpression
was ascertained by western-blot and immunoﬂuorescence
(Fig. 3d). In this experiment, invasion of THBS1-overexpressing
cells was increased (Fig. 3d).
Hypoxia increased THBS1 expression through TGFβ1 activa-
tion. Anti-angiogenic therapy using anti-VEGF antibodies (bev-
acizumab) is commonly used for the treatment of recurrent
GBMs25. Tumour hypoxia and a subsequent increase in HIF1α
expression are consequences of bevacizumab treatment in vivo,
which may lead to increased local invasion26. Since it has been
recently shown that bevacizumab treatment leads to an increase
in TGFβ1 mRNA expression in GBM27, we wanted to further
assess the function of THBS1 following bevacizumab treatment.
Bevacizumab-treated U87 tumours exhibited some invasive bor-
ders characterised by THBS1 deposits in the vicinity of invasive
strands (Supplementary Fig. 8A). In bevacizumab-untreated P3
tumours, THBS1 deposits were already observed in peripheral
areas but not in the tumour core (Fig. 4a). This was further
conﬁrmed by laser-capture microdissection and qPCR analysis
where THBS1 mRNA was found signiﬁcantly increased in the
invasive area when compared with the tumour centre (Fig. 4b). In
bevacizumab-treated P3 tumours, an increase in THBS1 expres-
sion was seen in the tumour core by western blot (Fig. 4a).
Moreover, under in vitro hypoxic conditions, P3 and U87 cells
increased THBS1 expression, as demonstrated by western blot
(Fig. 4c and Supplementary Fig. 8B). Hypoxia activated the
SMAD pathway as revealed by luciferase reporter experiments
(Fig. 4d and Supplementary Fig. 8C), and we showed by using
ELISA that THBS1 expression and secretion was inhibiting
using LY2157299 (Fig. 4e and Supplementary Fig. 8D). In the
highly angiogenic U87 glioma model treated with bevacizumab,
silencing of THBS1 by shRNA led to a decrease in tumour
expansion and invasion (Supplementary Fig. 8E). Survival was
signiﬁcantly increased when both THBS1 shRNA-transduced
U87 and P3 tumours were treated with bevacizumab (Fig. 4f
and Supplementary Fig. 8F).
CD47/THBS1 interaction is involved in GBM expansion. It has
recently been shown that TAX2, a 12 amino-acid peptide stretch
of CD47, speciﬁcally inhibits the THBS1/CD47 interaction,
causing necrosis in various tumour models18,28. In particular,
TAX2 inhibits THBS1/CD47 interactions at the surface of
endothelial cells. P3 cells highly express CD47 (Supplementary
Data 1) while exhibiting low CD36 in vivo expression (Supple-
mentary Data 1).
Since hypoxia induces THBS1 expression (Fig. 4c), we treated
P3 spheroids with TAX2 or control peptide under hypoxic
conditions (Fig. 5a). In this case, TAX2 signiﬁcantly inhibited
hypoxia-induced in vitro cell invasion (Fig. 5a). We next
investigated the effect of the various treatments on tumour
development in vivo. Blood vessel density was modiﬁed in all
treatment groups with a strong effect of the TAX2+ bevacizumab
combination on small vessels (Fig. 5b). Combination treatment
inhibited contra-lateral and single-cell invasion in the P3
intracranial tumour model in comparison to bevacizumab
treatment alone (Fig. 5c). Survival was increased when animals
were treated with combinatory treatment (Fig. 5d).
CD47 is a key player of GBM invasion. We have furthermore
reinforced our results by silencing CD47 in both P3 and U87 cells.
We have used single-cell track migration as well as spheroid
invasion assay. The spheroid invasion assay in collagen I with
CD47-silenced P3 cells showed signiﬁcant reduction of invasion
(Fig. 6a, b). The single-cell migration track assay with CD47-
silenced U87 cells demonstrated signiﬁcant inhibition of cell
Fig. 2 THBS1 expression is regulated by TGFβ1 via SMAD3 promoter binding. a Analysis of THBS1 expression in protein extracts from non-treated or
TGFβ1-treated U87 (left) and P3 (right) cells (24 or 48 h treatment). TGFβ1 was used at a concentration of 5 ng/ml. The graphs represent quantiﬁcations
of THBS1 signal normalised to Tubulin (n= 3). Densitometry analysis (right panels) is represented as fold induction compared to control. Student’s t-test P-
value: **P < 0.01; ****P < 0.0001. b ELISA experiment performed on U87 (left) and P3 (right) cell supernatants or lysates, treated with 5 ng/ml of TGFβ1,
10 µM of TGFβR inhibitor LY2157299 or combination treatment for 48 h. The graph represents a mean of four (U87) or three (P3) independent
experiments as fold induction to non-treated cells. c Representative immunoﬂuorescence images of starved U87 control or TGFβ1-treated cells (30min
TGFβ1 treatment with a concentration of 5 ng/ml) showing nuclear translocation of P-SMAD2, P-SMAD3 or SMAD4. Staining: Smads (green), Phalloidin
for F-Actin (red) and DAPI for nuclei (blue). Scale bars: 10 µm. The graph on the right represents a mean of three independent experiments (100 cells
analysed in each), as fold induction vs non-treated cells. d Schematic representation of SMAD3-binding sites on THBS1 promoter. Binding site 1 is located at
−1125/−1115 and binding site 2 at −110/−100 on the THBS1 promoter. e Luciferase promoter activity was measured by transfecting a PGL3 vector
containing the full-length THBS1 promoter (Full) or inserts deleted either in binding site 1 (Del1) or binding site 2 (Del2). A GFP plasmid was used as a
control. U87 (left) and P3 (right) cells were starved for 24 h and treated with 5 ng/ml of recombinant TGFβ1. The results are represented of three (U87) or
four (P3) independent experiments. All graphs are represented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not signiﬁcant (ANOVA)
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migration in comparison to U87 control cells (Supplementary
Fig. 9A, B). Next, we have conducted in vitro invasion experi-
ments in P3 shRNA CD47 or control cells stimulated or not with
puriﬁed full-length THBS1. The results show that knockdown of
CD47 signiﬁcantly impairs THBS1-induced tumour cell invasion
(Fig. 6c). Furthermore, survival studies in mice implanted with P3
CD47 knockdown or control cells showed signiﬁcant increase in
survival times in the CD47 knockdown group (Fig. 6d).
THBS1 is the gene with highest connectivity. To reinforce our
results at a global scale, we performed transcriptomics analysis via
RNA-sequencing of P3 tumours. GFP-labelled tumour cells from
both invasive and angiogenic areas of P3 were visualised and then
laser-microdissected prior to RNA isolation and sequencing
(Fig. 1c). Gene expression proﬁling and data analysis were per-
formed with respect to human and mouse RNA independently
using Xenome (Supplementary Data 1). Principle component
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analysis of the RNA-sequencing data conﬁrmed distinct tran-
scriptional proﬁles for central and invasive tumour areas (Sup-
plementary Fig. 10A). Differential expression analysis revealed
gene signatures comprising 520 genes that were higher expressed
in invasive areas and 1035 genes that were higher in central areas
for P3 tumours (Supplementary Fig. 10B and Supplementary
Data 2). Functional analysis of the gene signatures revealed
enrichment of Gene Ontology terms being highly relevant to
glioma biology (Supplementary Data 3). As expected, central
areas showed higher expression of multiple genes related to blood
vessel development, cell adhesion, inﬂammation, cell migration
and neurogenesis, whereas invasive areas expressed higher levels
of genes controlling chemotaxis, cell migration and cell com-
munication. To further assess potential cellular networks involved
in these processes, we used Ingenuity Pathway Analysis to search
within the invasive and angiogenic gene signatures for potential
secreted molecules involved in cell communication (Supplemen-
tary Data 2). This analysis identiﬁed TNF and TGFB1 as the most
signiﬁcantly overlapping regulators with 47 and 36 targets,
respectively. As previously mentioned, TGFB1 is known to con-
trol many processes of GBM development, and interestingly 20
out of its 36 targets were expressed higher in invasive areas
(Supplementary Fig. 10C). While focusing on the invasive area,
we further compared overexpressed genes that may contribute to
communication between the stromal compartment and the
tumour. Tumour Thrombospondin-1 (THBS1), Annexin II
(ANXA2) and PDGFB were found to have the highest con-
nectivity with genes of the stromal compartment (Fig. 7 and
Supplementary Data 3). THBS1 has high connectivity in the
invasive compartment of P3 tumours with collagens, TGFB1 and
integrins (Fig. 7). The signiﬁcance of the role of THBS1 is sup-
ported by an independent laser-capture microdissection and
qPCR analysis, which showed increase of THBS1 mRNA in the
invasive area when compared to the tumour core (Fig. 4b). These
data are in agreement with the functional analysis described
above and, thus, support a role of THBS1 in tumour cell invasion
in GBM.
Discussion
GBMs represent one of the most challenging tumours to treat
based on their location and their invasive behaviour in the brain.
These tumours also display an extensive cellular heterogeneity.
Therefore, elucidating the mechanisms of tumour progression is
important for the development of new and effective therapies.
In this article, we focused our attention on THBS1 to deter-
mine its involvement in GBM development. We showed that
(1) THBS1 expression is greater in high-grade glioma patients
samples when compared with low-grade gliomas; (2) THBS1
expression is regulated by TGFβ1 via SMAD3-binding sites; (3)
THBS1 is both expressed in tumour cells and vessels; (4) tumour-
derived THBS1 is involved in GBM invasion and expansion; (5)
anti-angiogenic treatment increases THBS1 expression through
hypoxia-induced TGFβ1; (6) tumour cell-bound CD47 is
involved in THBS1 effects; (7) network analysis demonstrates
THBS1 as the gene with the highest connectivity in the invasive
compartment.
The thrombospondin family has been shown to be involved in
tumour development and progression in several types of cancer29.
THBS1 has been shown to impair GBM growth and vascular-
isation30. Since THBS1 is a matricellular protein with a plethora
of regulatory functions, we set out to further elucidate its role
through a systematic analysis using multiple cell models and
assays with a focus on tumour cell invasion.
A classical paradigm for TGFβ activation relies on the idea
that stretching of the TGFβ-LAP protein by THBS1 is involved in
this process24. However, in our study, treatment of cells with
puriﬁed THBS1 did not increase ﬁbronectin expression and did
not lead to smad phosphorylation in the reporter assay. We then
knocked down endogenous THBS1 in cells that highly over-
express this molecule and also produce signiﬁcant amounts of
active TGFβ1. This did not alter active TGFβ1 concentrations
in the medium, which indicates that THBS1 does not activate
TGFβ1 in this case. We therefore sought to determine whether,
on the contrary, TGFβ1 was able to regulate THBS1 expression
in GBM. THBS1 expression has been reported to be regulated
by FGF, PDGF or E2F131, but only a few reports exist to support
regulation of THBS1 by the TGFβ pathway32,33. In our study,
only TGFβ1 but not TGFβ2, EGF, PDGF-BB or IL10 stimulated
THBS1 expression. TGFβ1-mediated induction of THBS1 is
regulated through SMAD3 phosphorylation and nuclear trans-
location. To obtain insights into the transcriptional regulation,
we mutated the two SMAD3-binding motifs in the THBS1 pro-
moter. One is located at −1125/−1115, whereas the second
corresponds to a −110/−100 site. We demonstrated that these
two domains have opposite effects on THBS1 transcription. The
ﬁrst one activates THBS1 transcription while the second one
drives inhibitory signals. The net result of THBS1 activation
by TGFβ1 may be due to the ratio of Smad binding to site 1 and
2 where binding to site 2 will be favoured. The existence of
different target sites has been published for E2F1 with one
activator and one repressor target sequences34. The control of
THBS1 transcription may involve more SMAD3 interactors
for deﬁning this positive and negative effects. Further studies on
THBS1 gene regulation will be performed for elucidating this
phenomenon.
Fig. 3 THBS1 controls invasion and growth of P3 tumour. a P3 cells were transduced with shRNA control or shRNA THBS1 (−1 and −2). P3 spheroid
invasion was measured in collagen I gels after 24 h. Arrows represent the migration distance from the spheroid core. Scale: 50 µm. The graph represents
the invasion results as means ± s.d. of four independent experiments each done in 6–8 replicates for each condition. ****P < 0.0001 (ANOVA). b Control
shRNA or THBS1 shRNA-transduced P3 cells were xenotransplanted into Ragγ2 C−/− mice. Representative images of tumours with invasive areas are
shown by Nestin staining (grey) with schematic representations (invasion in red dashed lines and tumour mass in black dashed lines). Scale: 200 µm.
The graphs on the right represent the number of small (<10 µm), medium (between 10 and 20 µm), large blood vessels (>20 µm) (upper panel) and the
invasion area (lower panel) of control shRNA and THBS1-1/-2 shRNA-transduced P3 tumours (average of 5 tumours with 8 sections/tumour analysed;
* means comparison of small vessels; # means comparison of medium size vessels). The graphs represent results as means ± s.d (n= 5 tumours analysed
per group). *P < 0.05; #P < 0.05; ##P < 0.01; ns, not signiﬁcant (ANOVA). c Kaplan–Meier survival curves of xenotransplanted mice with shTHBS1-1
(orange line), shTHBS1-2 (red line) or shControl (grey line) transduced P3 cells, based on the presence of neuropathological features (n= 8 mice per
group); P-values were calculated with log-rank test, **P-value < 0.01, ***P-value < 0.001. d P3 cells were transduced with pLA57-control or pLA57-THBS1
lentiviral constructs. Analysis of THBS1 and Tubulin expression in protein extracts from pLA57-control or pLA57-THBS1 P3 cells by western blot
(Upper panel) and by immunostaining (lower left panel), THBS1 (green) and F-actin (red) and nuclei (blue). Scale bar: 10 µm. pLA57-control or pLA57-
THBS1 P3 cell spheroid invasion was measured in collagen I gels after 24 h. The graph represents the results as means ± s.d of three independent
experiments each done in 6–8 replicates for each condition, **P < 0.01 (Student t-test)
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Our data are in apparent contradiction with the results of
Seliger and collaborators35. These authors reported that THBS1
expression is increased by lactate and that this in turn contributes
to TGFβ2 activation. Our data are completely opposed to these
published results and one can only speculate about the reason of
these differences. TGFβ activation was only studied by the
authors in the HTZ-349 cell line and not any other standard or
patient-derived glioma cell lines. The authors also studied TGFβ2
activation and not TGFβ1 activation. On the contrary, our study
provides robust data that are highly consistent in standard and
patient-derived cell lines.
As noted in this article, we have used the U87 cell line for a
number of functional experiments. Recently, a doubt has been
cast on the origin of this cell line36. Furthermore, U87 cells
classically grow as a very compact and round angiogenic tumour
in vivo. In our study, we have used both U87 cells and cells from
patient-derived tumours. The results derived from TGFβ1 and
THBS1 functional analysis were consistent for both U87 and
patient-derived cell lines. In addition, we analysed another U87-
derived cell line, U87 IRE1dn, which have very high THBS1 levels
and a pronounced invasive phenotype in vitro and in vivo23.
Experiments carried out on the U87 cell line showed impair-
ment of in vitro invasion after THBS1 silencing. In vivo, mouse
survival was increased in animals xenografted with U87 THBS1-
knockdown tumours when treated with anti-angiogenic therapy.
This is also consistent with the results obtained with the P3
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tumour model where THBS1-knock down in combination with
bevacizumab treatment led to a marked inhibition of both in vitro
and in vivo invasion, with a signiﬁcant impact on mouse survival.
A decrease in tumour mass was also observed under these con-
ditions. Taken together, these data indicate that THBS1 has a role
in both tumour expansion and invasion. THBS1 inhibition
reinforces the effect of anti-angiogenic treatments.
Bevacizumab treatment is known to decrease neo-angiogenesis
and restores, to some extent, the blood–brain barrier37. This
therapy may also induce evasive resistance through upregulation
of pro-invasive molecules via HIF1α expression3. Hypoxia has
previously been shown to induce THBS1 expression9,38, but the
mechanistic link was not established in these studies as no HIF1α
binding sequence is present in the THBS1 promoter. Indeed, our
data showed that hypoxia leads to TGFβ1 activation and nuclear
accumulation of Smad transcription factors in GBM, which is
consistent with the observation that the TGFβ1 promoter exhibits
a hypoxia-responsive element39. Furthermore, as described above,
we demonstrated mechanistically how Smad3 induces THBS1
expression.
A mimicking peptide based on the CD36-activating sequence
of THBS1 was developed (ABT-510), but had disappointing
results in clinical trials40. Other molecules are, at present, under
development28. One of those, the TAX2 peptide, is aimed at
targeting the interaction between THBS1 and CD47. CD47 is
expressed in endothelial cells, macrophages, and also in tumour
cells41. This ﬁnding that was conﬁrmed in our glioma cell lines
and tumours models. TAX2 as a stand-alone treatment showed
inhibitory activity in vitro under hypoxia in P3 cells and impaired
single-cell invasion in vivo. TAX2 alone also reduced vascular
density to some extent. TAX2 combined with bevacizumab led to
an inhibition of contra-lateral tumour invasion in the same
tumour model. This indicates that the CD47–THBS1 interaction
has a complex role in GBM development by acting on angio-
genesis, tumour invasion and expansion. These data are rein-
forced by CD47 knock down in glioma cells, which demonstrated
inhibition of migration, invasion and an increase in survival. Our
results are in agreement with recently published data where the
authors identiﬁed cell-surface signatures for GBM using a systems
biology approach42. The authors showed that CD47, besides other
regulatory molecules, exhibited positive enrichment after TGFβ
treatment and that knock down of CD47 inhibited U87 migra-
tion. Furthermore, a computational model of THBS1 regulation
has been recently established that links hypoxia-TGFβ-THBS1.
This also supports our experimental work43.
To reinforce our data, we choose a non-biased approach by
performing RNA-sequencing of central and invasive areas in the
intracranial P3 model. Firstly, we identiﬁed several important
players for GBM development including TGFβ1. Most strikingly,
THBS1 was among the most connected genes in our analysis in
the invasive area, which supports the functional analysis descri-
bed above.
Taken together, our results indicate that THBS1 has an
important role in the development of GBM and that a reversed
signalling pathway from TGFβ1 to THBS1 is involved. THBS1
may not only act in the angiogenic core of the tumour but also in
areas of tumour cell invasion. Furthermore, tumour cell-bound
CD47 is important for THBS1 activity in tumour cell invasion
(Fig. 8). Finally, THBS1 inhibition may be therapeutically
important for reinforcing the efﬁcacy of current anti-GBM
treatments by not only acting at the vascular compartment, but
also on invasive processes in the tumour periphery.
Methods
Ethical issues. Male RAGγ2C−/− mice were housed and treated in the animal
facility of Bordeaux University (“Animalerie Mutualisée Bordeaux”). All animal
procedures have been done according to the institutional guidelines and approved
by the local ethics committee (agreement number: 4611).
Patient material. Patients with preoperative MR imaging studies suggesting a
presumptive diagnosis of GBM (deﬁned as intracerebral mass lesion with contrast
enhancement area at post gadolinium T1-weighted MR) were included in the
study. Volumetric FLAIR and post gadolinium T1-weighted images of these
patients were obtained in the preoperative period and loaded into the neurona-
vigation plan (Brainlab workstation) to be available during surgery for intrao-
perative tracking. At surgery, various samples were collected at the peripheral
region of the tumour (invasive area deﬁned as FLAIR abnormalities around and
distant from post gadolinium T1 contrast enhancement ring) or at the tumour core
(deﬁned as contrast enhancement area at the tumour ring in post gadolinium T1-
weighted images). The site of collection was registered every time on the neuro-
navigation system and data were stored and collected for subsequent analysis. Part
of the samples was immediately frozen and stored in the tumour bank. Another
part of the samples was sent for routine histological and molecular analysis (IDH1
mutation, MGMT promoter methylation status, 1p/19q codeletion, ATRX
expression). Only patients with a histological diagnosis of GBM and IDH1wt
proﬁle were included. Patients gave their consent prior tissue analysis according to
the clinical guidelines. Informed written consent was obtained from all subjects
(Department of Neurosurgery, Humanitas, Milano according to Humanitas ethical
committee regulations, or from the Haukeland Hospital, Bergen, Norway). The
patient molecular proﬁle is detailed in Supplementary Table 1.
Intracranial tumour xenografts. U87, P3 spheroids were stereotactically
implanted into the brains of randomly chosen Ragγ2C−/− mice (8–12 weeks old).
Brieﬂy, GBM spheroids (5 spheroids of 104 cells per mouse) were implanted into
the right cerebral cortex using a Hamilton syringe ﬁtted with a needle (Hamilton,
Bonaduz, Switzerland) and following the procedure already described44. Mice were
treated with 10 mg/kg (mouse weight) of bevacizumab, or 10 mg/kg (mouse
weight) of TAX2, LSKL or control peptides. Mouse survival was based on the
presence of neuropathological features (body position, fur quality, eye position)
and weight. A minimum of 7 mice per group was chosen to yield enough statistical
power (P= 0.05), except for one experiment in which 5 mice per group were used
(Fig. 5d).
Fig. 4 THBS1 is induced by hypoxia through TGFβ1 activation. a Protein extracts from P3 tumour cores were analysed by western blot probed with anti-
THBS1 and anti-Tubulin antibodies (left panel). Representative images of P3 control or bevacizumab-treated tumours stained for THBS1 (brown) and
counterstained with haematoxylin (blue) are shown (right panels). Images represent the core and the invasive areas of both tumours. Scale bars: 100 µm.
b qPCR of THBS1 transcript from the core or the invasive area of P3 tumours, after laser microdissection. Three independent tumours were analysed,
results are represented as means ± s.d and compared to the tumour core. *P < 0.05 (Student t-test). c Immunoblots of protein extracts from P3 cells
exposed to hypoxia (1% O2) for 4, 6, 18, 24 or 48 h, and probed with anti-THBS1 or anti-Tubulin antibodies. The graph below represents ratios of THBS1
and Tubulin signal intensities. Results are represented as means ± s.d. of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ns, non-
signiﬁcant (Student t-test, comparison to time 0). d P3 cells were incubated under normoxia (21% O2) or hypoxia (1% O2) for 48 h and stimulated or
not with 5 ng/ml of recombinant TGFβ1 or 10 µM of LY2157299. Cells were transfected with SRE construct and luciferase activity was assessed.
Results are represented as means ± s.d. of four independent experiments. e ELISA experiments performed on P3 cell lysates and supernatants. Cells were
treated or not with 10 µM of TGFβR inhibitor LY2157299, in normoxic or hypoxic conditions for 48 h. The graph represents three independent experiments
as fold induction in comparison to non-treated cells (mean ± s.d.). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, non-signiﬁcant (ANOVA).
f Kaplan–Meier survival curves of mice with intracranially implanted control (grey lines), THBS1-1 (orange lines) or THBS1-2 (red lines) shRNA-transduced
P3 cells. Animals were treated or not with Bevacizumab (Bev) (n= 7 mice per group); P-values were calculated with log-rank test; *P-value < 0.05;
**P-value < 0.01; ***P-value < 0.001
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Reagents and antibodies. The detailed information of all antibodies (primary and
secondary) used in this study is listed in Supplementary Tables 4 and 5. The
sequences of siRNA Smad3 are listed in Supplementary Table 6. The primer
sequences used for RTqPCR are listed in the same table. TGFβ1 recombinant
protein was purchased from Peprotech (100-21), puriﬁed THBS1 (R&D System,
3074-TH-050), recombinant TGFβ2 (Peprotech, 100-35B), EGF (Peprotech,
AF100-15), PDGF-BB (Sigma, SRP3138) and IL-1b (RD Systems, 201-LB/C).
TAX2 peptide (CEVSQLLKGDAC) and scramble control peptide (LSVDES-
KAQGIL) were synthesised and puriﬁed by Genecust (Dudelange, Luxembourg)
and controlled for composition and purity through electrospray ionisation-mass
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spectrometry (ESI-MS) and HPLC. Peptides were solubilized in the appropriate
culture medium for in vitro assays (DMEM or Neurobasal medium), or in normal
saline solution (0.9% (w/v) NaCl) for in vivo experiments. Cells were treated with
10 µg/ml of Tunicamycin (Sigma) or 10 µM of LY2157299 (TGFβ receptor I
inhibitor or Galunisertib). Animals from the treatment group received one weekly
i.p. injection of bevacizumab (10 mg/kg) every 2 days all along the experiment.
Laser capture microdissection and RNA-sequencing. Coronal brain sections (30
µm thickness) were made using a CM3050-S microtome (Leica, Wetzlar, Germany)
and mounted on 1 mm polyethylene-naphthalate membrane glass slides (P.A.L.M.
Microlaser Technologies AG, Bernried, Germany) that have been pretreated to
inactivate RNase. Subsequently, sections were, dehydrated in a series of pre-cooled
ethanol baths (40 s in 95% and twice 40 s in 100%) and air-dried. Laser micro-
dissection of samples was performed using a PALM MicroBeam microdissection
system version 4.6 equipped with the P.A.L.M. RoboSoftware (P.A.L.M. Microlaser
Technologies AG, Bernried, Germany). Laser power and duration were adjusted to
optimise capture efﬁciency. Microdissection was performed at ×5 magniﬁcation.
Four tumours were analysed for each condition, and ﬁve caps were collected for
each tumour type. Samples were collected in adhesives caps and resuspended in a
guanidine isothiocyanate-containing buffer (RLT buffer from RNeasy minikit,
Qiagen, Chatsworth, USA) with 10 µl/ml β-mercaptoethanol, and stored at −80 °C
until extraction was done. Total RNA was extracted from microdissected tissues
using the RNeasy® mini Kit (Qiagen, Hilden, Germany) according to the
Fig. 5 THBS1/CD47 interaction in P3 tumour invasion and growth. a P3 cells were included into collagen I gels and then incubated in normoxia (21 % O2) or
hypoxia (1 % O2). P3 spheroid invasion was measured in collagen I gels after 24 h. Scale: 50 µm. The graph represents the results as means ± s.d. of three
independent experiments, each done in 6–8 replicates for each condition. *P < 0.05; ns, non-signiﬁcant (ANOVA). b P3 tumours were treated with 10mg/
kg (BW) of bevacizumab (Bev), control peptide (control), TAX2 alone (TAX2) or in combination (Bev+ TAX2). Tumours sections were stained with anti-
CD31 antibody. Scale: 20 µm. The graphs below represent the vascular density (left panel) and the quantiﬁcation of vessel types according to size (right
panel: small vessels < 10 μm; medium size vessels between 10 and 20 μm; large vessels > 20 μm) (average of 5 tumours with 8 sections/tumour analysed).
Results are represented as means ± s.d. *P < 0.05; ***P < 0.001; ****P < 0.0001 for small vessel comparison; ##P < 0.01 for medium vessel comparison; ns,
non-signiﬁcant (ANOVA). c P3 tumours were stained for Nestin (grey) to evaluate contra-lateral or single-cell invasions (black dashed lines around tumour
edges and red dashed lines around invasive areas). Scale: 100 µm. The graphs below represent core (left panel), contra-lateral invasion (medium panel)
and single-cell invasion (right panel) areas of tumours from treated and untreated mice (average of 5 tumours with 8 sections/tumour analysed). Results
are represented as means ± s.d. *P < 0.05; **P < 0.01; ****P < 0.0001; ns, non-signiﬁcant (ANOVA). d Kaplan–Meier survival curves of P3 xenotransplanted
mice treated with control peptide, TAX2 and bevacizumab alone or in combination (n= 5 mice per group); P-values were calculated with log-rank test; *P-
value < 0.05; ***P-value < 0.001
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Fig. 6 Tumour-associated CD47 controls glioma cell invasion and motility. a Immunoblots of protein extracts from control or CD47-1/-2 shRNA-
transduced P3 cells probed with anti-CD47 or anti-Tubulin antibodies. b P3 cells were transduced with control or CD47 (−1 and −2) shRNAs. P3 spheroid
invasion was measured in collagen I gels after 24 h. Scale: 50 µm. The graph below represents the results as means ± s.d. of three independent experiments
each done in 6–8 replicates for each condition. **P < 0.01; ****P < 0.0001 (ANOVA). c Effect of THBS1 on P3 cells transduced with control or CD47-1
shRNAs. Full-length THBS1 was used at a concentration of 10 µg/ml and invasion in collagen I gels was measured after 24 h. The results are expressed as
means ± s.d. of three independent experiments each done in 6–8 replicates for each condition. **P < 0.01; ****P < 0.0001; ns, non-signiﬁcant (ANOVA).
d Kaplan–Meier survival curves of mice bearing control or CD47-1 shRNA-transduced P3 tumours (n= 5 mice per group); P-values were calculated with
log-rank test; ***P-value < 0.001
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manufacturer’s protocol. The integrity of the RNA was checked by capillary elec-
trophoresis using the RNA 6000 Pico Labchip kit and the Bioanalyser 2100
(Agilent Technologies, Massy, France), and quantity was estimated using a
Nanodrop 1000 (Thermo Scientiﬁc, Waltham, USA). The RNA integrity number
(RIN) above 7/8.
RNA-sequencing for P3 tumours. Overall, 500 ng was used as input material for a
Low Input Ribozero treatment using the Epicentre Ribo-Zero Gold Kit–Low Input
(HMR), and subsequently puriﬁed using Ampure XP beads. The samples were then
analysed on the Agilent 2100 Bioanalyzer and all of the depleted RNA was used as
input material for the ScriptSeq v2 RNA-Seq Library Preparation protocol. Fol-
lowing 14 cycles of ampliﬁcation, the libraries were puriﬁed using Ampure XP
beads. Each library was quantiﬁed using Qubit, and the size distribution assessed
using the Bioanalyzer.
These ﬁnal libraries were pooled in equimolar amounts using the Qubit and
Bioanalyzer data. The quantity and quality of each pool was assessed by the
Bioanalyzer and subsequently by qPCR using the Illumina Library Quantiﬁcation
Kit from Kapa on a Roche Light Cycler LC480II according to manufacturer’s
instructions.
The template DNA was denatured according to the protocol described in the
Illumina User guide and loaded at 12.5 pM or 13 pM concentration. The
sequencing was carried out on two lanes of an Illumina HiSeq2500 at 2 × 125 bp
paired-end sequencing with v4 chemistry.
Bioinformatics analysis. Reads quality ﬁltering, species assignment and genomic
alignment: Read quality check and ﬁltering has been performed using NGS QC
Toolkit v.2.3.345 with default parameters. Less than 1% of the reads has been
discarded at this step. Unpaired reads have been kept and represent 0.005% of the
data. In order to assign the reads to Human and Mouse, we have used Xenome
v.1.0.146. It is a two-step process. During the ﬁrst step, we created the genome
index ﬁles built from EMBL release 84 (Human GRCh38 and Mouse mm10). We
used the index ﬁles to classify the sequence as host or graft separately for paired
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and single reads. The genomic alignment was performed with Bowtie247 with
default parameters on the same reference genomes as used for Xenome. Reads with
quality mapping score lower than 10 were discarded.
Differential expression between the tumour core and invasive areas: We
ﬁrst assigned reads to hg38 (human) and mm10 (mouse) gene models retrieved
from48. Using the R packages GenomicFeatures and GenomicAlignments49, 25,446
and 24,423 genes were analysed in human and mouse respectively. In order to
compute differential expression, we performed two-class comparisons between
tumour core and invasive samples using the R package DESeq250. Differentially
expressed genes were deﬁned by using an upper threshold on the P-value of
0.01 after correction for multiple testing using the method of Benjamini and
Hochberg51.
Functional enrichment: The R packages ClusterProﬁler52 and DOSE53 were
used to identify functional enrichment in groups of genes in human and mouse.
These packages give access to the Gene Ontology (GO) categories (molecular
function, biological process, cellular component), KEGG pathways, the Disease
Ontology (DO) and the Network of Cancer Genes (NCG).
Network building: Protein–protein interaction networks representing putative
signalling events occurring in the invasive tumour microenvironment/ECM were
constructed as followed (i) Mouse expression data were annotated using human
orthologs of mouse genes retrieved from EnsEMBL release 85 and used for
subsequent analysis (www.ensembl.org/). (ii) Host and tumour data were subset for
genes that were associated to Gene Ontology terms Extracellular Space
(GO:0005615), Extracellular Region (GO:0005576) and External side of plasma
membrane (GO:0009897). (iii) Genes expressed by the host were determined as
present in the extracellular compartment if their average expression was higher
than 2. (iv) Genes expressed in tumours and overexpressed in invasive regions were
selected from the differential expression analysis. (iv) Non-redundant interactions
between proteins represented by the gene sets identiﬁed in (iii) and (iv) were
retrieve from BIOGRID v. 3.4.14054. (v) Visualisation of the resulting network
was performed using Cytoscape55 and the community clustering algorithm GLay
within the Clustermaker plugin (www.cgl.ucsf.edu/cytoscape/cluster/clusterMaker.
shtml).
THBS1/TGFB1 expression between GBM grades: Analysis of THBS1 and
TGFβ1 expressions in gliomas of various grades was performed using data from
Sun et al.56. The fold changes are represented in log2 scale. This gives a log2 fold
change of 8.59− 6.32= 2.27. To convert this to a linear fold change, we calculate
2 to the power of 2.27 (22.27= 4.82).
Cell culture and transfection. All cells used for phenotypic and functional studies
have been further characterised more in detail by cGH array (P3) and by cell
authentication (U87) using Promega Powerplex21 Kit (Euroﬁns, GE). The U87
(ATCC) and P3 glioma cell lines were regularly tested for contamination and were
all mycoplasma free. Cells were cultured in Dulbecco’s Modiﬁed Eagle’s medium
(DMEM, Thermo Fisher Scientiﬁc) supplemented with 10% Fetal Bovine Serum
(FBS), 5% antibiotics (Penicillin and Streptavidin) and 5% L-glutamine. U87 cells
were cultured at 37 °C, 5% CO2 and split at 70–90% of conﬂuence with 0.25%
Trypsin. P3 spheroids were extracted for P3 tumours and cultured in agar-layered
ﬂasks for few weeks. The patient-derived cell lines P3, BL9 and BL13 were isolated
by enzymatic digestion from P3 tumours or from patient samples (BL9 and BL13)
and then cultured in Neurobasal Medium (NBM, Thermo Fisher Scientiﬁc) sup-
plemented with B27, 0.2% heparin (100 U) and 20 ng/ml basal FGF. Cell trans-
fection was performed using GeneCellin Reagent (Eurobio) according to the
manufacturer instruction, for luciferase plasmids (see Methods below). Cells
were also cultured in hypoxic conditions (1% O2).
Small interfering RNA knockdown experiments. For transient inhibition of
Smad3 expression, cells were transfected with annealed siRNA. Transfections were
performed using lipofectamine RNAimax kit (Fisher 10601435) in accordance
with the manufacturer protocol, with a ﬁnal concentration of 20 nM in media
without antibiotics. After transfection, cells were washed twice with PBS and fresh
complete media was added for 48 h.
shRNA constructs, lentiviral production and cell infection. The shRNA target
sequences for THBS1 and CD47 are listed in Supplementary Table 6. Gain-of-
Function experiments were assessed by overexpressing full-length human THBS1
in a pcDH1 lentiviral vector (Invitrogen). The lentiviral particles were produced
by transfecting HEK293T with pMD2.G (VSV-G, viral envelope) and psPAX2
(packaging construct) with 20 µg of bacterial plasmids. Viruses were collected
after 48 h of transfection and then ﬁltered (0.22 µm ﬁlter). Infectious particles
were titrated with scale infections of U87 cells.
RNA extraction, semi-quantitative and quantitative RT-PCR. Total RNA was
extracted from cells using the TriZol reagent protocol (Invitrogen). After quanti-
ﬁcation, reverse transcription was done with 2 μg of total RNA using the High
Capacity cDNA Reverse Transcription kit (Applied Biosystems). Human THBS1,
human CD47 and β-Actin mRNA expression levels were measured by real-time
quantitative polymerase chain reaction (qRT-PCR) using Power SYBRGreen PCR
Master Mix (Applied Biosystems) on StepOne (Applied Biosystems), according
to the manufacturer’s protocol. Primer sequences are listed in Supplementary
Table 7. The relative abundance of transcripts was calculated by using β-actin
transcript quantity as standard. The quantitative RT-PCR experiments were carried
out in triplicate on RNA isolated from three independent cell cultures.
Promoter and luciferase reporter assay. Wild-type THBS1 promoter was
ampliﬁed by PCR using platinum pfu (Invitrogen), sequenced and cloned in pGL3-
basic vector at SacI and NheI sites. Del1 and Del2 mutants were ampliﬁed by PCR,
sequenced and cloned at the same sites. Luciferase promoter activity was measured
by quantifying Renilla and Fireﬂy Luciferase activities with the microplate reader
Inﬁnite F200 Pro (TECAN) using the Dual-Glo Luciferase Assay System (Pro-
mega), according to the manufacturer’s instructions. U87 cells were transfected
with the pRL-TK vector and either with plasmids carrying the full-length promoter
of THBS1, or Del1 or Del2 mutants for promoter studies.
For SMAD reporter assay, cells were transfected with SBE4-luc vector
containing SMAD responsive elements. For promoter studies, a control pEGFP
plasmid was used to assess transfection efﬁciency. The pRL-CMV vector (Promega)
allowed control and normalisation of the transfection. All transfections and
measurements were performed in ﬁve different wells and repeated at least three
times.
Western blot. Two procedures were used for protein lysis, depending of the
proteins of interest. (1) Cells were washed twice with phosphate-buffered saline
(PBS) and dissolved in lysis buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5%
NP-40, 1%TritonX-100, 1 mM EDTA) supplemented with protease and phos-
phatase inhibitors cocktails (Roche). Protein concentration was quantiﬁed by
Bradford assay (Euromedex). Cell lysates were resuspended in Laemmli Buffer
(62.5 mM Tris pH 6.8, 10% glycerol, 2.5% SDS, 2.5% β-mercaptoethanol). (2) Cells
were washed twice in PBS and directly lysed in Laemmli Buffer. All protein extracts
were then boiled for 5 min and separated by SDS–PAGE. Proteins were electro-
blotted onto a polyvinylidene diﬂuoride (PVDF) membranes (Fisher Scientist,
10344661). Membranes were incubated with blocking buffer (EuroBio 927-40003)
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for 1 h, probed overnight at 4 °C with the primary antibodies of interest, followed
by detection using secondary antibodies coupled to Fluoroprobes (Supplementary
Table 5) and Odyssey infra-red imaging system (Li-Cor Biosciences, Nebraska,
US). Densitometry analysis was performed using Fiji software. Uncropped
immunoblots are depicted in Supplementary Figures 11 and 12.
Human THBS1 ELISA. The Quantikine ELISA for Human THBS1 (R&D Systems)
was used according to the manufacturer’s protocol. Proteins from lysates were
extracted with 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% NP-40, 1% TritonX-
100, 1 mM EDTA supplemented with protease and phosphatase inhibitors cock-
tails (Roche). Protein contents from lysates and supernatants were determined by
using the BCA protein assay kit (Pierce).
Indirect immunoﬂuorescence staining. Cells were seeded on glass coverslips and
ﬁxed 10 min with 4% paraformaldehyde at room temperature, then washed in PBS.
Cells were permeabilised 10 min with 0.1% TritonX-100, washed in PBS and
incubated for 1 h with blocking buffer (PBS containing 2% FBS and 1% BSA) at
room temperature. Cells were incubated with primary antibodies diluted in
blocking buffer overnight at 4 °C, washed with PBS, and incubated with secondary
antibodies diluted in blocking buffer (Supplementary Table 5). DAPI was used to
label nuclei (Fisher Scientist, 10374168). Coverslips were mounted using Prolong
Gold antifade reagent (Fisher Scientist, 11559306).
Histological and immunohistological analyses. Tissues embedded in OCT were
cut in frozen sections of 10 μm using the microtome LEICA CM1900. For histo-
logical analyses, frozen sections were stained with haematoxylin and eosin. For
immunoﬂuorescence on histological sections, frozen sections were processed as
described in the indirect immunoﬂuorescence staining section.
Patient parafﬁn-embedded sections were deparafﬁnised in xylene and hydrated
serially in 100, 95, and 80% ethanol. Endogenous peroxidase was quenched in 3%
H2O2 in PBS for 1 h. Slides were then incubated with antibodies (Supplementary
Table 4) overnight at 4 °C. Sections were washed three times in PBS, and antibody
binding was revealed using the Ultra-Vision Detection System anti-Polyvalent
HRP/DAB kit according to the manufacturer instructions (Lab Vision). Finally, the
slides were counterstained with haematoxylin and washed in distilled water. After
dehydration and mounting, THBS1 expression localisation was analysed by using
IHC proﬁler from Fiji® Software. For THBS1 immunostaining, tissue microarrays
were used to compare patient grade samples (numbers B17016c and B17015a,
BioMax, US).
Invasion assays in collagen I gels. P3 spheroids were prepared 3 days respectively
before inclusion by seeding of 104 cells in neurobasal medium with 0.4%
methylcellulose (Sigma) in a U-bottom 96 wells plate (Falcon). A solution of 1 mg/
ml of collagen I (Fisher Scientiﬁc) was prepared in PBS with 7.2 mM NaOH. After
30 min of incubation on ice, spheroids were individually picked, washed in PBS and
included in the collagen solution. After 45 min at 37 °C in a cell incubator, neu-
robasal medium with the different treatments is added. P3 spheroid invasion areas
are measured after 24 h with FIJI software. The total area was delineated by two
independent investigators as well as the central spheroid core. An invasive index
was calculated by the ratio of the total spheroid surface and the spheroid core.
Invasion assays on U87 cells. U87 cells were seeded on 0.2 mg/ml Matrigel
coatings into a ImageLock 96 well plate. The day after, wounds were created using
IncucyteTM wound maker and a 2 mg/ml Matrigel layer was deposited on top of
the cells. The plate was then processed for invasion using IncucyteTM device.
Quantiﬁcations of vascular density, invasive index. Vascular density: This was
estimated as the ratio of the vessel surface (CD31 staining) to the total tumour
surface (Nestin staining). Each experiment was analysed with an average of 5
tumours with 8 sections/tumour using Fiji software57. Evaluation of vessel length:
3–4 images stained with CD31 were analysed for evaluating blood vessel quality
(small vessels < 10 µm length, medium vessels between 10 and 20 µm length, and
large vessels > 20 µm length) using counter from Fiji57.
Invasive index: This was estimated by measuring the surface of the invasive area
(mm2). Each experiment was analysed with an average of 5 tumours with
8 sections/tumour using Fiji57.
Live-cell microscopy. To assess cell motility, U87 cells were seeded at a density of
2 × 104 cells per well on Matrigel coated glass bottom 24-well plates (Greiner),
as published before58. Hoescht 33342 (10 ng/ml) was added to label the nuclei.
Live-cell imaging was performed with a Eclipe Ti Nikon video microscope coupled
with NIS analysis software, based on a ×10 NA 0.30 objective lens (Nikon), a
Hamamatsu Digital CCD C10600-10B camera, and an environmental chamber to
maintain cells at 37 °C in a 5% CO2 humidiﬁed atmosphere (Life Imaging Services).
Videos were acquired every 15 min for a period of 24 h in brightﬁeld and blue
ﬁlters (Hoescht 33342). Mean cell displacements were calculated with the ImageJ
plugin TrackMate. The software was used to automatically track nuclei and
characterise their trajectories among stacks of images.
Statistical analysis. Statistical analysis was performed using the Graphpad soft-
ware. Multiple comparisons were performed with one-way analysis of variance,
followed by Tukey post hoc tests and with one-way ANOVA Bonferroni multiple
comparison test. Statistical comparison between two groups was performed by
using the Mann–Whitney U test.
Survival analysis were analysed by using log-rank test.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data are available within the Article and Supplementary Files, or available from the
corresponding authors on reasonable request. Transcriptomics data are available from the
SRA: PRJNA320047 or the European Nucleotide Archive: PRJEB23786. We have also
uploaded supplementary material to the Figshare repository (for e.g.: https://ﬁgshare.com/
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